WO1993019773A1 - Lyophilized somatotropin formulations - Google Patents
Lyophilized somatotropin formulations Download PDFInfo
- Publication number
- WO1993019773A1 WO1993019773A1 PCT/US1993/003182 US9303182W WO9319773A1 WO 1993019773 A1 WO1993019773 A1 WO 1993019773A1 US 9303182 W US9303182 W US 9303182W WO 9319773 A1 WO9319773 A1 WO 9319773A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- somatotropin
- solution
- buffer
- lyophilization
- diluent
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 166
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 166
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000009472 formulation Methods 0.000 title description 3
- 239000003085 diluting agent Substances 0.000 claims abstract description 62
- 239000000872 buffer Substances 0.000 claims abstract description 34
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000004108 freeze drying Methods 0.000 claims abstract description 31
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 20
- 238000013019 agitation Methods 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 101
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 19
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 18
- 239000006172 buffering agent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 4
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims description 4
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000006174 pH buffer Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims 4
- 230000000975 bioactive effect Effects 0.000 claims 3
- 125000000185 sucrose group Chemical group 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000004475 Arginine Substances 0.000 abstract description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 102000015731 Peptide Hormones Human genes 0.000 description 2
- 108010038988 Peptide Hormones Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000025240 Pituitary deficiency Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- the " present invention relates to novel solutions of somatotropins which remain clear for an extended period of time and which remain clear when subjected to mechanical agitation, and to kits for making the solutions.
- Somatotropins also known as growth hormones, are polypeptide hormones secreted by the pituitary glands of many animal species. These hormones are valuable for a number of therapeutic uses, and compositions comprising somatotropin can be administered in the treatment of pituitary deficiency in humans and gastrointestinal bleeding or to promote the healing of bone fractures and accelerate the healing of contusions and other wounds. Somatotropins also are useful in promoting meat and milk production in animals when administered through various drug-releasing devices or by injection. (See E.J. Tur an, "Some Effects of Pituitary Anterior Growth Factor" Thesis: Purdue
- aggregation of adsorbed somatotropin molecules can take place to give soluble or insoluble polymeric forms. This aggregation will manifest itself, for example, as turbidity of the solution or as biological inactivation of the somatotropin protein on stirring or shaking of the aqueous solutions (See A.F. Henson et al., J. Colloid Interface Sci. 32: 162 (1970)).
- somatotropin solutions which remain clear for extended periods and which do not become cloudy or precipitate when subjected to mechanical agitation.
- the somatotropin solutions contain a lyophilized somatotropin composition containing about 1 part somatotropin per 2 to 8 parts arginine HCl on a weight basis, the pH of the composition prior to lyophilization within the range of about 7.2 to about 8.5, which is dissolved in a diluent. If the pH of the somatotropin composition prior to lyophilization was less than 7.8, the diluent comprises EDTA, a nonionic surfactant and a buffer.
- the diluent comprises EDTA and a nonionic surfactant and optionally, further can comprise a suitable buffer or nonbuffering agent if desired. If a non-buffering agent is added, desirably a buffer is not also added to the diluent, although both agents can be used.
- kits for making the solutions include a vial containing the lyophilized somatotropin composition containing about 1 part somatotropin per 2 to 8 parts arginine HCl on a weight basis.
- the kits also include a vial containing a biocompatible diluent comprising EDTA and a nonionic surfactant.
- the diluent also can comprise a buffer or non-buffering agent. If the pH of the somatotropin composition prior to lyophilization was less than 7.8, the vial containing the diluent further comprises a buffer.
- the vial optionally can contain a buffer or nonbuffering agent.
- the diluent can be added to the lyophilized somatotropin composition and the resultant mixture then shaken to dissolve the somatotropin.
- This invention is directed to somatotropin solutions which remain clear for extended periods and which do not become cloudy or precipitate when subjected to mechanical agitation such as shaking or vortex-mixing.
- a somatotropin solution which remains "clear” is a solution in which the somatotropin does not precipitate after it is dissolved in the diluent.
- These somatotropin solutions will remain clear after several days of storage, typically at least about 5 days.
- the somatotropin solutions maintain clarity for at least about 5 days when stored, typically, for example, at about 25°C. At slightly higher storage temperatures, the somatotropin solutions maintain clarity, but possibly for a shorter period of time.
- a solution which remains clear will have an apparent absorbance measurement at 360 n (O.D.
- the somatotropin solutions contain a lyophilized somatotropin composition, the pH of which prior to lyophilization was at least about 7.2, generally within the range of from about 7.2 to about 8.5. If the pH of the somatotropin composition prior to lyophilization was " less than 7.8, the diluent comprises EDTA, a nonionic surfactant and a suitable buffer to stabilize the final somatotropin solution. If the pH of the somatotropin composition prior to lyophilization was 7.8 or higher, the diluent comprises EDTA and an nonionic surfactant and, optionally, a buffer or nonbuffering agent.
- a non-buffering agent is added to the diluent, desirably a buffer is not also added to the diluent, although both agents can be used. Neither the buffer nor nonbuffering agent need be used if the pH of the . somatotropin composition prior to lyophilization was at least 7.8, but either can be provided to adjust or maintain the isotonicity of the resultant somatotropin solution such that it is less hypertonic. This is desirable if the somatotropin solution will be injected into animals.
- the choice of a suitable additive can be made based on a number of factors, including, for example, cost, presence on the FDA GRAS list, autoclavability, chemical stability, lack of interaction with the somatotropin and bioco patibility.
- the lyophilized somatotropin composition is prepared by dissolving arginine HCl with somatotropin, adjusting the pH of the solution to at least 7.2, preferably from 7.2 to 8.5, and removing any undissolved material by filtration or centrifugation.
- the somatotropin and arginine HCl solution then is lyophilized using standard procedures known in the art.
- the solution to be lyophilized generally contains about 1 part somatotropin per 2 to 8 parts arginine HCl on a weight basis and preferably comprises about 1 part somatotropin per 3 parts arginine HCl.
- the solution preferably contains 10 to 150 mg/ml somatotropin and 30 to 450 mg/ml arginine HCl and has a final pH of at least 7.2.
- the solution to be lyophilized contains 30 mg/ml somatotropin and 90 mg/ml arginine HCl and has a final pH of from 7.8 to 8.5.
- the somatotropin which may be employed in the lyophilized somatotropin composition of this invention can be any somatotropin, including natural or recombinant bovine, porcine, human, avian, ovine, or equine somatotropin.
- the somatotropin employed is porcine somatotropin.
- somatotropin is intended to include the full length natural or recombinant somatotropin as well as derivatives thereof that have growth-promoting capabilities.
- Derivatives include biologically active fragments or analogs >of the polypeptide hormone, such as delta 7 porcine somatotropin, which has an amino acid sequence corresponding to that of porcine somatotropin, less the first seven amino acids of the mature, full length hormone (described in European Patent Application Publication No. 0 104 920 to Biogen N.V. ) .
- biologically active as used herein means a polypeptide that, following its administration to a living being, has a demonstrable effect on a biological process of that living being.
- the somatotropins employed in the compositions of this invention can be metal-associated somatotropins.
- Metal-associated somatotropin is produced by the addition of salts of transition metals to an aqueous solution containing the somatotropin.
- the salts of the transition metals form insoluble complexes with the somatotropin, thus precipitating the somatotropin out of the solution.
- the metal-associated somatotropins comprise the somatotropin molecules and metal ions such as Zn +2 , Cu +2 , Co +2 , Mn +2 , Fe +2 or Fe +3 .
- metal-associated somatotropins contain ligand bonds between the metal ion and the nitrogen atoms of some of the amino acid residues in the somatotropin molecule.
- the metal-associated somatotropins are used as starting materials for making the lyophilized somatotropin compositions.
- the metals likely are not associated with the somatotropin once the metal-associated somatotropin is lyophilized, although they are present in the lyophilized somatotropin composition.
- the presence of the transition metal in the product has been shown to have no significant adverse effect on the bioactivity of the somatotropin when the product is administered to a living being.
- the somatotropin solutions of this invention are made by dissolving the lyophilized somatotropin composition with a diluent such that the pH of the final solution is at least about 7.2, typically from about 7.2 to about 8.5, and preferably from about 7.2 to about 8.2. If the pH of the solution is greater than about 8.5, " degradation of the protein can occur. Typically, about 0.5 to about 40 mg lyophilized somatotropin composition are provided per ml of diluent.
- the final concentration of the somatotropin solution is about 10 to 30 mg lyophilized somatotropin composition per ml of diluent and most preferably about 20 mg lyophilized somatotropin composition per ml of diluent.
- the weight of the lyophilized somatotropin composition will be the total of the weight of the arginine HCl and the weight of the somatotropin contained in the lyophilized somatotropin composition.
- the diluent comprises EDTA, a nonionic surfactant and a buffer.
- the diluent comprises EDTA and a nonionic surfactant and optionally also comprises a buffer or nonbuffering agent.
- the pH of the final somatotropin solution will be the same as the pH of the diluent.
- the pH of the lyophilized somatotropin composition dissolved in the diluent will determine the pH of the final somatotropin solution.
- the concentration of EDTA provided in the diluent is at least 1.5 mM, and is preferably from about 1.5 mM to about 10 mM.
- the concentration of EDTA used in the diluent desirably is at least 1.0 mM, and is preferably from about 1.0 mM to about 10 mM.
- Surfactants which are suitable for use in the diluent include polyoxyethylene-23 lauryl ether (Brij 35), Tween 80, polyoxyethylene-20 cetyl ether (Brij 58), and other polyoxyethylene nonionic surfactants having similar hydrophilic/hydrophobic balance (HLB).
- Such nonionic surfactants have been noted in the prior art as stabilizing and preserving activity in purified enzymes. (See T. Kitani et al., Eur. J. Biochem. 119: 177-181 (1981); M. Pritchard et al., Biochem. Biophvs. Res. Commun. 100: 1597-1603 (1981); Seely et al.. Biochemistry, Vol. 21, No.
- the surfactant is present in a concentration ranging from about 0.08% to 2.0%. If the surfactant utilized is Brij 35, the concentration of the Brij 35 is at least 0.08%, and preferably is from about 0.1% to about 0.2%. If the surfactant is Tween 80 or Brij 58, the concentration preferably is from about 0.1% to about 1.0%.
- a buffer is provided in the diluent to increase the stability of the somatotropin solution.
- the buffer can be Tris HCl, phosphate, or some other neutral, host- compatible pH buffer.
- the buffer is present in a concentration ranging from about 0.2 M to about
- Tris HCl generally has a concentration of at least 0.2 M, and is preferably from about 0.2 M to about 0.3 M.
- a buffer as described above or a non-buffering agent can be added to the diluent, if desired, to adjust or maintain the isotonicity of the resultant somatotropin solution.
- the non-buffering agent also is host-compatible. Such agents include sucrose, trehalose, or NaCl.
- the non- buffering agent if present, generally is provided at a concentration from about 0.05 M to about 0.5 M. When sucrose or trehalose is utilized as the non-buffering agent, preferred concentrations are within the range of from about 0.1 to about 0.3 M. When NaCl is utilized as the non-buffering agent a concentration of from 0.05 M to 0.15 M generally is preferred.
- the somatotropin compositions of this invention can be made using kits containing a vial of the lyophilized somatotropin composition as discussed above and a vial containing the diluent discussed above.
- the diluent can be added to the lyophilized somatotropin composition and the resultant product shaken to dissolve the somatotropin.
- the somatotropin solutions of this invention can be used for further processing or can be administered directly to animals.
- the solution generally can be stored for at least about 5 days at ambient temperatures, typically about 25°C, without becoming cloudy.
- the solutions also can be stored at slightly higher temperatures, although the solutions may maintain their clarity a shorter period of time.
- These solutions also can be subjected to mechanical agitation, such as shaking or mixing, without precipitation of the somatotropin from the solution.
- the somatotropin in these solutions maintains its biological activity and can be administered to animals in accordance with conventional techniques to promote growth.
- solution clarity was determined by visual inspection and/or by measuring the apparent absorbance at 360 nm (O.D. 360); a wavelength where somatotropins have no intrinsic absorbance.
- O.D. 360 apparent absorbance at 360 nm
- the somatotropin solution was placed in the sample cuvette and the O.D. 360 determined using a Shimadzu UVU160 spectrophotometer. A diluent solution which did not contain somatotropin was used in the reference cuvette. Quartz cuvettes were used in all studies.
- "clear" solutions are those which have an O.D. 360 of less than 0.10.
- Example 1 Thirty-three grams of Zn-associated porcine somatotropin (pST), made in accordance with the procedures disclosed in published European Patent Application No. 83300803.9, and 90 grams of arginine HCl were dissolved in one liter of sterile water. The pH was adjusted to 7.8 by the addition of aqueous HCl or NaOH and insolubles were removed by filtration through a polyvinylidene difluoride membrane. The clarified solution then was lyophilized.
- pST Zn-associated porcine somatotropin
- the resulting formulation (termed the "lyophilized porcine somatotropin (pST) composition") contained approximately 30 g pST per 90 g arginine HCl, due to the loss of about 10% of the original 33 g of pST as insoluble during the filtration step.
- Example 2 Solid arginine HCl (1.92 g) was added to a non-Zn complexed pST solution containing 0.639 g pST in 21.6 ml of a pH 9.8, 0.46 mM sodium carbonate buffer. The arginine was dissolved by stirring and the pH of the solution was adjusted to 7.8 by the dropwise addition of 1 M NaOH. The resulting solution contained approximately 30 mg/ml pST and 90 mg/1 arginine. 5 Aliquots (7.2 ml) of this solution were pipetted into three 50-ml vials, frozen at -80°C, and lyophilized.
- This lyophilized pST composition readily dissolved in 200 mM Tris HCl, 2 mM EDTA, 0.15% Brij 35 (pH 7.8) at 20 mg/ml (dissolution time ⁇ 3 minutes). The 0 resulting solution was clear by visual inspection.
- Zinc-associated pST Zn-pST
- non-metal complexed pST non-Zn pST
- lyophilized pST composition 0 made as described in Example 1
- Zinc-associated pST Zn-pST
- non-metal complexed pST non-Zn pST
- lyophilized pST composition 0 made as described in Example 1
- solution clarity was determined by visual observation arid by 5 measuring turbidity at 360nm.
- Table 1 shows that - only the lyophilized pST composition gave a clear solution after dissolution under these conditions. The results are shown in Table 1.
- Table 1 Table 1
- the somatotropin solutions containing a Brij 35 concentration of at least 0.08% resulted in a clear solution after vortexing the lyophilized pST composition in the diluent under these conditions.
- the somatotropin solutions containing a Brij 35 concentration of at least 0.08% resulted in a clear solution after vortexing the lyophilized pST composition in the diluent under these conditions.
- Brij 35 concentration of less than 0.08% did not remain clear following mechanical agitation by vortex mixing.
- Example 5 Forty mg aliquots of lyophilized pST composition were weighed into 2 dram glass vials and dissolved in the diluent containing 200 mM Tris HCl, 0.10% Brij 35 at the following EDTA concentrations and final pH:
- EDTA concentration of at least 1.5 mM resulted in a clear solution for at least 10 days after dissolution of the lyophilized pST composition in the diluent under these conditions.
- somatotropin solutions with a pH of 7.6 or greater, containing an EDTA concentration of at least 1.0 mM resulted in a clear solution for at least 5 days after dissolution of the lyophilized pST in the diluent under these conditions.
- Example 6 Forty mg aliquots of lyophilized pST composition were weighed into 16 two-dram glass vials. Two ml of the following diluents were added: 1. 300 mM Tris HCl, 0.15% Brij 35, 1.5 mM EDTA, pH 7.4
- a Tris HCl concentration of at least 200 mM must be employed in a diluent containing 0.15% Brij 35 and 1.5 mM EDTA at a pH of 7.4 in order for the somatotropin solution to remain clear for six days.
- Solutions 6-8 in Table 4 illustrated that an EDTA concentration of at least 1.5 mM was necessary, in addition to a Brij 35 concentration of 0.15% and a Tris HCl concentration of 200 mM at a pH of 7.2, in order for the somatotropin solution to remain clear for six days.
- the somatotropin solution remained clear after six days when the diluent comprised 0.15% Brij 35, 2 mM EDTA and either 1%, 5%, or 10% sucrose or 0.2 M, 0.1 M or 0.0 M NaCl and the final pH of the samples were approximately 7.8-7.9.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93912120A EP0639984A1 (en) | 1992-04-07 | 1993-04-05 | Lyophilized somatotropin formulations |
JP5517756A JPH08502021A (en) | 1992-04-07 | 1993-04-05 | Biocompatible somatotropin solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86476892A | 1992-04-07 | 1992-04-07 | |
US864,768 | 1992-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993019773A1 true WO1993019773A1 (en) | 1993-10-14 |
Family
ID=25344034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/003182 WO1993019773A1 (en) | 1992-04-07 | 1993-04-05 | Lyophilized somatotropin formulations |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0639984A1 (en) |
JP (1) | JPH08502021A (en) |
CN (1) | CN1089249C (en) |
AU (1) | AU4278393A (en) |
CA (1) | CA2133737A1 (en) |
WO (1) | WO1993019773A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035116A1 (en) * | 1994-06-17 | 1995-12-28 | Applied Research Systems | Hgh containing pharmaceutical compositions |
US6013773A (en) * | 1996-02-02 | 2000-01-11 | Mitsui Chemicals, Inc. | Pharmaceutical preparation containing human growth hormone |
US6664234B1 (en) | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
US6719990B2 (en) | 2000-02-24 | 2004-04-13 | Monsanto Technology Llc | Non-aqueous injectable formulations for extended release of somatotropin |
US6719992B2 (en) | 2000-06-26 | 2004-04-13 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
US9452157B2 (en) | 2012-07-06 | 2016-09-27 | Alfa Wassermann S.P.A | Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof |
US10525134B2 (en) | 2012-06-05 | 2020-01-07 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
US10590408B2 (en) | 2016-02-18 | 2020-03-17 | Ge Healthcare Uk Limited | Method and composition for biomolecule stabilization |
CN116421566A (en) * | 2023-02-16 | 2023-07-14 | 高邮市人民医院 | Preparation containing polyethylene glycol recombinant human growth hormone |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
CN103751769B (en) * | 2013-12-25 | 2015-08-19 | 楼秀余 | A kind of lyophilizing recombinant human somatropin capsule and preparation method thereof |
CN112618482A (en) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | Novel protein formulations |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131864A2 (en) * | 1983-07-13 | 1985-01-23 | Hoechst Aktiengesellschaft | Denaturation-resistant aqueous solutions of proteins, process for preparing them and their use |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
EP0303746A1 (en) * | 1987-08-21 | 1989-02-22 | Mallinckrodt Group Inc. | Stabilization of growth promoting hormones |
WO1990002560A1 (en) * | 1988-09-12 | 1990-03-22 | Pitman-Moore, Inc. | Swine growth promotion |
WO1990014100A2 (en) * | 1989-05-15 | 1990-11-29 | Pitman-Moore, Inc. | Somatotropin for increasing fertility in animals |
-
1993
- 1993-04-05 JP JP5517756A patent/JPH08502021A/en active Pending
- 1993-04-05 EP EP93912120A patent/EP0639984A1/en not_active Withdrawn
- 1993-04-05 CA CA002133737A patent/CA2133737A1/en not_active Abandoned
- 1993-04-05 AU AU42783/93A patent/AU4278393A/en not_active Abandoned
- 1993-04-05 WO PCT/US1993/003182 patent/WO1993019773A1/en not_active Application Discontinuation
- 1993-04-06 CN CN93104030A patent/CN1089249C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131864A2 (en) * | 1983-07-13 | 1985-01-23 | Hoechst Aktiengesellschaft | Denaturation-resistant aqueous solutions of proteins, process for preparing them and their use |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
EP0303746A1 (en) * | 1987-08-21 | 1989-02-22 | Mallinckrodt Group Inc. | Stabilization of growth promoting hormones |
WO1990002560A1 (en) * | 1988-09-12 | 1990-03-22 | Pitman-Moore, Inc. | Swine growth promotion |
WO1990014100A2 (en) * | 1989-05-15 | 1990-11-29 | Pitman-Moore, Inc. | Somatotropin for increasing fertility in animals |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035116A1 (en) * | 1994-06-17 | 1995-12-28 | Applied Research Systems | Hgh containing pharmaceutical compositions |
US6013773A (en) * | 1996-02-02 | 2000-01-11 | Mitsui Chemicals, Inc. | Pharmaceutical preparation containing human growth hormone |
US7048938B2 (en) | 2000-02-24 | 2006-05-23 | Monsanto Technology Llc | Non-aqueous injectable formulations for extended release of somatotropin |
US6719990B2 (en) | 2000-02-24 | 2004-04-13 | Monsanto Technology Llc | Non-aqueous injectable formulations for extended release of somatotropin |
US7037516B2 (en) | 2000-06-26 | 2006-05-02 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
US6719992B2 (en) | 2000-06-26 | 2004-04-13 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
US7030091B2 (en) | 2000-06-30 | 2006-04-18 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
US6664234B1 (en) | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
US10525134B2 (en) | 2012-06-05 | 2020-01-07 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
US9452157B2 (en) | 2012-07-06 | 2016-09-27 | Alfa Wassermann S.P.A | Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof |
US10590408B2 (en) | 2016-02-18 | 2020-03-17 | Ge Healthcare Uk Limited | Method and composition for biomolecule stabilization |
CN116421566A (en) * | 2023-02-16 | 2023-07-14 | 高邮市人民医院 | Preparation containing polyethylene glycol recombinant human growth hormone |
Also Published As
Publication number | Publication date |
---|---|
CN1078910A (en) | 1993-12-01 |
AU4278393A (en) | 1993-11-08 |
CA2133737A1 (en) | 1993-10-14 |
CN1089249C (en) | 2002-08-21 |
EP0639984A1 (en) | 1995-03-01 |
JPH08502021A (en) | 1996-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0904099B1 (en) | Pharmaceutical formulation containing human growth hormone, histidine and a non-ionic detergent | |
CN102387784B (en) | Lyophilized recombinant vwf formulations | |
KR100457485B1 (en) | Stable Transglutaminase Formulation and Manufacturing Method Thereof | |
JP3065662B2 (en) | Parathyroid hormone preparations | |
EP0618807B1 (en) | A stabilized pharmaceutical formulation comprising growth hormone and histidine | |
EP1044016B1 (en) | Stabilised insulin compositions | |
EP1932519B1 (en) | Protein stabilization formulations | |
CA2139358C (en) | Human growth hormone aqueous formulation | |
EP0603159A2 (en) | Human growth hormone formulation | |
WO1993019773A1 (en) | Lyophilized somatotropin formulations | |
CA2026149A1 (en) | Stabilized aqueous formulations of small peptides | |
US4637834A (en) | Aqueous protein solutions which are stable towards denaturing, processes for their preparation and their use | |
KR20020064141A (en) | Freeze Dried HGF Preparations | |
EP0804223B1 (en) | Hgh containing pharmaceutical compositions | |
JPH10507181A (en) | Pharmaceutical formulation comprising growth hormone and valine | |
EP0420964A1 (en) | Lyophilized peptide formulations | |
US20060074011A1 (en) | Compositions providing for increased IGF-I solubility | |
EP2142174A1 (en) | Stable aqueous g-csf formulations | |
WO2003006053A1 (en) | HUMAN INTERFERON-β FORMULATIONS | |
KR880002037B1 (en) | Interferon composition and preparation method thereof | |
US5140010A (en) | Stabilized aqueous formulations of thymopentin | |
EP1028748B1 (en) | Compositions providing for increased igf-i solubility | |
WO1995002411A1 (en) | Stabilised polypeptide growth factor formulation at low ph | |
JP2005232177A (en) | hGH CONTAINING PHARMACEUTICAL COMPOSITION | |
US20160095904A1 (en) | Stabilized liquid formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD SK UA VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993912120 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2133737 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1993912120 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993912120 Country of ref document: EP |